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Abstract 
Some new platinum(II) complexes have been prepared, of general formula trans-
[PtCl2(PPh3){NH(Bu)CH2Ar}], where the dimension of the Ar residue in the secondary amines has 
been varied from small phenyl to large pyrenyl group. The obtained complexes, tested in vitro 
towards a panel of human tumor cell lines showed an interesting antiproliferative effect on both 
cisplatin-sensitive and -resistant cells. For the most cytotoxic derivative 2a the investigation on the 
mechanism of action highlighted the ability to induce apoptosis on resistant cells and interestingly, 
to inhibit the catalytic activity of topoisomerase II. 
 
Keywords: transplatinum(II) complexes; antiproliferative activity; DNA topoisomerases. 
 
 
 
 
* corresponding author. Phone: +39 0498275712; fax: +39 0498275366; e-mail address: 
lisa.dallavia@unipd.it 
  
 2 
1. Introduction 
 
Since the discover of cis-[PtCl2(NH3)2] (cisplatin) anticancer properties,
1
hundreds of new platinum(II) complexes have been tested for their antiproliferative activity.
2
 
Among them, trans complexes also containing phosphorous based ligands,
3
 are promising, and in 
some cases they have shown a good activity towards cisplatin resistant cell lines.
3a,h
 We have 
recently prepared a series of [PtCl2(PPh3)(L)] complexes,
4
 were L was a neutral ligand. Most of 
them were tested in vitro
4c,d
 against HeLa, H460 and A549 human tumor cell lines and our results 
showed that a higher antiproliferative activity could be observed in the case of trans compounds 
and L = R2NH.
4d
 In particular, the highest antiproliferative activity was observed for L = 
NH(CH2CH2OH)2 and the investigation about its mechanism of action highlighted the capacity to 
affect the mitochondrial functions,
4c
 with a mode of action different from cisplatin. Moreover, its 
interaction with a phospholipid bilayer, used as a model of the cellular membrane, proved to be 
different from that of cisplatin,
5
 suggesting that even the mode of crossing the cellular membrane 
could be different. 
In this contest and with the aim of expanding knowledge about structure-activity relationship, we 
prepared four new platinum(II) complexes, of general structure trans-
[PtCl2(PPh3){NH(Bu)CH2Ar}], where the dimension of the aromatic residue on the secondary 
amines was varied (Ar = Phenyl, 1-Naphtyl, 9-Anthracenyl, 2-Pyrenyl). 
In addition, trans-[PtCl2(PPh3)(p-Tolu)] (p-Tolu = 4-methylaniline) was prepared, as a model 
devoid of the CH2 spacer between the aromatic moiety and the coordinated nitrogen. 
In the present work, we report the synthesis and characterization of the secondary amines 
ArCH2NHBu and of the corresponding trans-platinum(II) complexes, together with the 
antiproliferative activity towards a panel of tumor cell lines, both sensitive and resistant to cisplatin. 
For the most interesting complex, the study on the mechanism of action is reported. In particular, 
the death pathway on resistant cells was analysed by flow cytometry and moreover, the binding to 
salmon testes DNA and the effect on cell cycle were determined in comparison with cisplatin. 
Finally, the ability to interfere with the catalytic activity of the nuclear enzymes topoisomerase I 
and II was investigated. 
  
 3 
2. Material and methods 
 
2.1. General experimental conditions 
All manipulations were performed under a dinitrogen atmosphere, if not otherwise stated. Solvents 
and liquid reagents were dried according to reported procedures.
6
 
1
H-, 
13
C-, 
31
P and 
195
Pt NMR 
spectra were recorded with a Bruker ‘‘Avance DRX400’’ spectrometer, in CDCl3 solution if not 
otherwise stated. Chemical shifts were measured in ppm (δ) from TMS by residual solvent peaks 
for 
1
H- and 
13
C-, from aqueous (D2O) H3PO4 (85%) for 
31
P- and from aqueous (D2O) 
hexachloroplatinic acid for 
195
Pt-NMR. A sealed capillary containing C6D6 was introduced in the 
NMR tube to lock the spectrometer to the deuterium signal when non-deuterated solvents were 
used. FTIR spectra in solid phase were recorded with a Perkin–Elmer ‘‘Spectrum One’’ 
spectrometer, equipped with an ATR accessory. IR data are expressed in cm
-1
. Elemental analyses 
(C, H, N) were performed at Dipartimento di Scienze e Tecnologie Chimiche, Università di Udine. 
Cis-[PtCl2(NCMe)(PPh3)]
4a
 was prepared according to a reported procedure. 
 
2.2. Synthesis of ArCH2NHBu 
In a round-bottomed flask equipped with magnetic stirrer, condenser and dropping funnel, a 
solution of ArCHO in ethanol ([ArCHO] ≈ 0.37 mol/L) was treated with butylamine 
([BuNH2]/[ArCHO] = 2.1 mol/mol). The mixture was refluxed until the complete conversion of 
ArCHO into ArCH=NHBu was reached [IR spectroscopy, ῦCHO (≈1680 cm
-1
) vs ῦCH=N (≈1640 cm
-
1
)]. The solution was cooled (0°C) and an excess of NaBH4 ([NaBH4]/[ArCHO] = 2.5/1 mol/mol) 
was added in small portions. When the vigorous evolution of dihydrogen ceased, the mixture was 
warmed (25°C) and stirring was continued (10 h). Ethanol and excess BuNH2 were evaporated 
under reduced pressure, water was added and the aqueous solution was extracted in Et2O (3 × 100 
mL). Organic extracts were washed with water (3 × 30 mL) and dried over anhydrous Na2SO4, then 
solvents were evaporated under reduced pressure. For each amine prepared the purification method, 
the percentage isolated yield and the spectroscopic characterization are reported: 
 
2.2.1. N,N-Benzylbutylamine (PhCH2NHBu, 1a):
7
 Ar = Ph; filtration over a short package of 
anhydrous Al2O3; colourless liquid; 73%. Anal. Calcd. for C11H17N: C 80.9, H 10.5, N 8.6 %. 
Found: C 80.8, H 10.3, N 8.6 %. IR (ATR): 3340 (b), 3087, 3064, 3028, 2957, 2928, 2872, 2815, 
1495, 1454, 1120, 1076, 1029, 730, 696; 
1
H NMR: 7.27-7.18 (m, 5H, HArom), 3.73 (s, 2H, PhCH2), 
2.58 (t, 2H, J = 7.3 Hz, NHCH2), 2.50 (bs, 1H, NH), 1.46 (quint, 2H, J = 7.3 Hz, NHCH2CH2), 1.28 
(sest, 2H, J = 7.5 Hz, CH2CH3), 0.87 (t, 3H, J = 7.5 Hz, CH3); 
13
C NMR:139.8, 128.4, 128.3, 127.0, 
53.8, 48.9, 31.9, 20.4, 13.9. 
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2.2.2. N,N-(1-Naphtylmethyl)butylamine (1-NpCH2NHBu, 1b):
7
 Ar = 1-Np; distillation under 
reduced pressure (130°C/0.5 torr); colourless oil; 98%. Anal. Calcd. for C15H19N: C 84.5, H 9.0, N 
6.6 %. Found: C 85.0, H 9.2, N 7.0 %. IR (ATR): 3350 (b), 3048, 2956, 2928, 2870, 2828, 1590, 
1576, 1509, 1457, 1396, 1377, 1333, 1236, 1225; 
1
H NMR: 8.11-7.41 (m, 7H, HAr), 4.22 (s, 2H, 
ArCH2), 2.73 (t, 2H, J = 7.0 Hz, NHCH2CH2), 1.73 (bs, 1H, NH), 1.53 (m, 2H, NHCH2CH2), 1.35 
(m, 2H, CH2CH2CH3), 0.91 (t, 3H, J = 7.0 Hz, CH3); 
13
C NMR: 136.0, 133.9, 131.8, 128.8, 127.7, 
126.1, 126.0, 125.6, 125.4, 123.6, 51.6, 49.8, 32.2, 20.6, 14.1. 
 
2.2.3. N,N-(9-Anthracenylmethyl)butylamine (9-AnthCH2NHBu, 1c):
8
 Ar = 9-Anth; the sample 
was used in the following synthesis without further purification; yellow, low melting solid; 88%. 
Anal. Calcd. for C19H21N: C 86.6, H 8.0, N 5.3 %. Found: C 86.3, H 8.0, N 5.2 %. IR (ATR): 3330 
(b), 3052, 2954, 2926, 2858, 1623, 1524, 1445, 1376, 1337, 1320, 1158, 1107, 952, 882, 839, 788, 
727; 
1
H NMR: 8.37-8.31 (m, 3H, HAr), 7.96 (d, 2H, HAr), 7.53-7.41 (m, 4H, HAr), 4.71 (s, 2H, 
ArCH2), 2.84 (t, 2H, J = 7.3 Hz, NHCH2CH2), 2.37 (bs, 1H, NH), 1.56 (m, 2H, NHCH2CH2), 1.33 
(m, 2H, CH2CH2CH3), 0.88 (t, 3H, J = 7.3 Hz, CH3); 
13
C NMR: 131.6, 131.1, 130.4, 129.2, 127.4, 
126.2, 125.0, 124.1, 50.1, 45.6, 32.0, 20.5, 14.0. 
 
2.2.4. N,N-(2-Pyrenylmethyl)butylamine (2-PyrCH2NHBu, 1d):
9
 Ar = 2-Pyr; the sample was 
used in the following synthesis without further purification; colourless solid; 98%. Anal. Calcd. for 
C21H21N: C 87.4, H 7.4, N 4.8 %. Found: C 87.7, H 7.3, N 4.8 %. IR (ATR): 3380 (b), 3039, 2952, 
2927, 2894, 2859, 2814, 1601, 1586, 1475, 1443, 1415, 1393, 1369, 1331, 1299, 1183, 1117, 1094, 
839, 824, 801, 743, 710, 679; 
1
H NMR: 8.34-7.96 (m, 9H, HAr), 4.45 (s, 2H, ArCH2), 2.76 (t, 2H, J 
= 7.0 Hz, NHCH2CH2), 1.54 (m, 3H, NHCH2CH2), 1.35 (m, 2H, CH2CH2CH3), 0.89 (t, 3H, J = 7.0 
Hz, CH3); 
13
C NMR: 134.2, 131.4, 130.9, 130.6, 129.1, 127.6, 127.5 (2C), 127.0, 126.9, 125.9, 
125.1, 125.0 (2C), 124.7, 123.2, 51.9, 49.8, 32.3, 20.6, 14.1. 
 
2.3. Synthesis of trans-[PtCl2(PPh3){NH(Bu)CH2Ar}] (2a-d) 
In a round-bottomed flask equipped with magnetic stirrer, condenser and dropping funnel, a 
suspension of cis-[PtCl2(CH3CN)(PPh3)] in 10 mL of 1,2-DCE was refluxed (84°C) and treated 
with a solution containing the secondary amine (ArCH2)BuNH in 2.0 mL of the same solvent (cis-
[PtCl2(CH3CN)(PPh3)]/[R2NH] molar ratio =1/1.2). The progress of the reaction was monitored by 
31
P NMR spectroscopy until the complete conversion of the precursor into the desired product was 
observed (3 h). Solvent was eliminated under vacuum (0.01 mmHg), the residue was dissolved in 
CH2Cl2 (5 mL) and treated with heptane (10 mL). Solid products were recovered by filtration and 
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dried under vacuum (0.01 mmHg). The same procedure was followed for the preparation of trans-
[PtCl2(PPh3)(p-Tolu)] (3). For each of the trans-[PtCl2(PPh3)(amine)] complexes the amine used, 
the isolated % yield and the spectroscopic characterization are indicated: 
 
2.3.1 trans-[PtCl2(PPh3){NH(Bu)(CH2Ph)}] (2a): PhCH2NHBu; 50%; Anal. Calcd. for 
C29H32Cl2NPPt: C 50.4, H 4.7, N 2.0 %. Found: C 50.3, H 4.4, N 2.0 %. IR (ATR): 3195m, 2964, 
2929, 2871, 2792, 2358, 1811, 1588, 1496, 1480, 1384, 1312, 1097s, 1010, 977, 911, 866, 707m, 
691s; 
1
H NMR: 7.66-7.32 (m, 20H, Harom), 4.50 (dd, [
2
JH-H = 12.4 Hz, 
3
JH-H = 6.7 Hz], 1H, 
PhCHH), 4.03-3.81 (bs [
2
JH-Pt = 73.0 Hz]+m, 2H, NH + PhCHH), 3.25 (m, 1H, NHCHH), 2.66 (m, 
1H, NHCHH), 2.24 (m, 1H, NHCH2CHH), 1.86 (m, 1H, NHCH2CHH), 1.38 (m, 2H, CH2CH3), 
0.92 (t, 3H, CH3); 
13
C NMR: 148.0, 134.7 (d, [JC-P = 10.5 Hz]), 130.7 (d, [JC-P = 2.0 Hz]), 130.0, 
129.8, 127.9 (d, [JC-P = 56.5 Hz]), 127.9 (d, [JC-P = 11.2 Hz]), 56.3, 50.7, 31.0, 20.4, 13.9; 
31
P NMR: 
5.25 (
1
JP-Pt = 3576 Hz); 
195
Pt NMR: -3669 (
1
JPt-P = 3576 Hz). 
 
2.3.2. trans-[PtCl2(PPh3){NH(Bu)(CH2Np)}] (2b): 1-NpCH2NHBu; 86%; Anal. Calcd. for 
C33H34Cl2NPPt·0.5(CH2Cl2): C 51.3, H 4.5, N 1.8%. Found: C 52.3, H 4.5, N 1.9% IR (ATR): 
3250, 1481, 1433, 1265, 1098, 1014, 800, 726, 690; 
1
H NMR: 8.24 (d, 1H, HNp), 7.87 (m, 2H, 
2HNp), 7.64-7.32 (m, 19H, 4HNp + Ph), 5.05 (d, [
2
JH-H = 12.0 Hz], 1H, NpCHH), 4.37-4.17 (bs [
2
JH-
Pt = 81.0 Hz]+ d, [
2
JH-H = 12.0 Hz], 2H, NH + NpCHH), 3.29 (m, 1H, NHCHH), 2.51 (m, 1H, 
NHCHH), 2.20 (m, 1H, NHCH2CHH), 1.77 (m, 1H, NHCH2CHH), 1.31 (m, 1H, CHHCH3), 1.22 
(m, 1H, CHHCH3), 0.82 (t, 3H, CH3); 
13
C NMR: 134.8 (d, [
2
JC-P = 10.2 Hz]), 134.0, 131.7, 131.4, 
130.8, 129.4, 129.0, 128.9 (d, [
1
JC-P = 62 Hz]), 127.9 (d, [
2
JC-P = 11.1 Hz]), 127.9, 127.1, 126.1, 
125.2, 123.3, 53.7, 49.9, 31.1, 20.0, 13.8; 
31
P NMR: 4.09 (
1
JP-Pt = 3580 Hz); 
195
Pt NMR: -3620 (
1
JPt-
P = 3580 Hz). 
 
2.3.3. trans-[PtCl2(PPh3){NH(Bu)(CH2Anthr)}] (2c): 9-AnthrCH2NHBu; 57%; Anal. Calcd. for 
C37H36Cl2NPPt: C 56.1, H 4.6, N 1.8%. Found: C 55.7, H 4.5, N 1.8%. IR (ATR): 3250, 3047, 
2921, 1622, 1525, 1481, 1433, 1310, 1186, 1156, 1099, 
1
H NMR: 8.49 (m, 2H, 2HAnth), 8,02 (m, 
2H, 2HAnth), 7.72-7.32 (m, 20H, 5HAnth + Ph), 5.42 (d, [
2
JH-H = 13.5 Hz], 1H, AnthCHH), 5.27 (d, 
[
2
JH-H = 13.5 Hz], 1H, AnthCHH), 4.50 (bs, [
2
JH-Pt = 80.0 Hz], 1H, NH), 3.46 (m, 1H, NHCHH), 
2.30 (m, 1H, NHCHH), 2.16 (m, 1H, NHCH2CHH), 1.73 (m, 1H, NHCH2CHH), 1.21 (m, 1H, 
CHHCH3), 1.08 (m, 1H, CHHCH3), 0.71 (t, 3H, CH3); 
13
C NMR: 134.8 (d, [
2
JC-P = 10.2 Hz]), 
131.5, 131.1, 130.8, 129.4, 128.9 (d, [
1
JC-P = 62 Hz]), 128.6, 127.9 (d, [
2
JC-P = 11.0 Hz]), 127.0, 
126.7, 125.3, 124.0, 49.5, 48.0, 31.3, 19.8, 13.7; 
31
P NMR: 4.16 (
1
JP-Pt = 3573 Hz); 
195
Pt NMR: -
3618 (
1
JPt-P = 3573 Hz). 
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2.3.4. trans-[PtCl2(PPh3){NH(Bu)(CH2Pyren)}] (2d): 2-PyrenCH2NHBu; 63%; Calcd. for 
C39H36Cl2NPPt·CH2Cl2: C 53.3, H 4.2, N 1.6%. Found: C 54.1, H 4.1, N 1.6%. IR (ATR): 3229, 
3042, 2957, 2929, 1590, 1482, 1433, 1185, 1100, 1078, 999, 850; 
1
H NMR: 8.49 (d, 1H, HPyren), 
8,20-8.00 (m, 7H, 7HPyren), 7.98 (t, 1H, HPyren) 7.59-7.13 (m, 15H, Ph), 5.28 (bs, 1H, PyrenCHH), 
4.63 (bs, 1H, PyrenCHH), 4.39 (bs, [
2
JH-Pt = 79.0 Hz], 1H, NH), 3.43 (m, 1H, NHCHH), 2.60 (m, 
1H, NHCHH), 2.22 (m, 1H, NHCH2CHH), 1.81 (m, 1H, NHCH2CHH), 1.33 (m, 1H, CHHCH3), 
1.23 (m, 1H, CHHCH3), 0.82 (t, 3H, CH3); 
13
C NMR: 134.8 (d, [
2
JC-P = 10.2 Hz]), 131.7, 131.4, 
130.9, 130.7, 129.7, 128.9 (d, [
1
JC-P = 61 Hz]), 127.9 (d, [
2
JC-P = 10.7 Hz]), 127.5 (2C), 126.2 (2C) , 
125.5 (2C), , 125.2, 124.9, 124.8, 123.0 (2C), 53.9, 50.4, 31.2, 20.1, 13.9; 
31
P NMR: 4.05 (
1
JP-Pt = 
3590 Hz); 
195
Pt NMR: -3618 (
1
JPt-P = 3590 Hz). 
 
2.3.5. trans-[PtCl2(PPh3)(p-Tolu)] (3): 4-methylaniline (p-toluidine); 95%; m.p.: 251-254°C (lit. 
247-249°C);
10
 Anal. Calcd. for C25H24Cl2NPPt: C 47.3, H 3.8, N 2.2 %. Found: C 47.0, H 3.7, N 2.3 
%. IR (ATR): 3212, 3128, 3052, 1559, 1509, 1480, 1433, 1097, 814, 754, 745, 691; 
1
H NMR: 7.72-
7.67 (m, 6H, Harom Phosphine), 7.46-7.38 (m, 9H, Harom Phosphine), 7.32 (d, 2H, J = 8.2 Hz, Harom 
Toluidine), 7.14 (d, 2H, J = 8.2 Hz, Harom Toluidine), 5.31 (bs, 2H, 
2
JH-Pt = 46.0 Hz, NH2), 2.35 (s, 
3H, CH3); 
13
C NMR: 136.8, 135.2, 134.8 (d, [
2
JC-P = 10.5 Hz], 130.9, 129.9, 128.3 (d, [
1
JC-P = 64.0 
Hz]), 128.0 (d, [
2
JC-P = 11.3 Hz]), 121.5, 20.9; 
31
P NMR: 3.63 (
1
JP-Pt = 3773 Hz); 
195
Pt NMR: -3614 
(
1
JPt-P = 3773 Hz). 
 
2.4. Inhibition Growth Assay 
HeLa (human cervix adenocarcinoma cells) were grown in Nutrient Mixture F-12 [HAM] (Sigma 
Chemical Co.); H460 (large cell lung carcinoma) and MSTO-211H (human biphasic mesothelioma) 
were grown in RPMI 1640 (Sigma Chemical Co.) supplemented with 2.38 g/L Hepes, 0.11 g/L 
pyruvate sodium and 2.5 g/L glucose; A2780 (human ovarian carcinoma) and A2780cis (human 
ovarian carcinoma cisplatin-resistant) were grown in RPMI 1640 (Sigma Chemical Co.). 1.5 g/L 
NaHCO3, 10% heat-inactivated fetal calf serum (Invitrogen), 100 U/mL penicillin, 100 μg/mL 
streptomycin, and 0.25 μg/mL amphotericin B (Sigma Chemical Co.) were added to the media. The 
cells were cultured at 37°C in a moist atmosphere of 5% carbon dioxide in air. Cells (2.5-3 x 10
4
) 
were seeded into each well of a 24-well cell culture plate. After incubation for 24 h, various 
concentrations (from 0.25 to 20 M) of the test agents were added to the complete medium and 
incubated for a further 72 h. Stock solutions of new complexes were made in dimethylsulfoxide at 5 
mM concentration and then diluted with complete medium in such a way that the final amount of 
solvent in each well did not exceed 0.5%. Cisplatin was dissolved in 0.9% NaCl. A Trypan blue 
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assay was performed to determine cell viability. Cytotoxicity data were expressed as GI50 values, 
i.e., the concentration of the test agent inducing 50% reduction in cell number compared with 
control cultures. 
 
2.5. Evaluation of apoptotic cell death by Annexin V-FITC and propidium iodide staining 
To detect phosphatidylserine translocation from the inner face to the outer surface of plasma 
membrane, a FITC Annexin V Apoptosis Detection Kit I (BD Pharmigen) was used. 
A2780cis cells (2.0 x 10
5
) were seeded into each cell culture plate in complete growth medium. 
After incubation for 24 h the test agents were added at the indicated concentrations and cells were 
incubated for a further 18 h. After treatment, cells were centrifuged and resuspended at 10
6
 cells/mL 
in binding buffer. Cell suspensions (100 L) were added with Annexin V-FITC and propidium 
iodide (PI) as indicated by the supplier’s instructions, and incubated for 15 min at room temperature 
in the dark. The populations of Annexin V-negative/PI-negative cells (viable), Annexin V-
positive/PI-negative cells (early apoptosis), Annexin V-positive/PI-positive cells (late apoptosis) 
and Annexin V-negative/PI-positive cells (necrosis) were evaluated by FACSCanto II flow 
cytometer (Becton–Dickinson, Mountain View, CA).11 
 
2.6. Cell cycle analysis 
A2780 cells (2.0 x 10
5
) were seeded into each cell culture plate in complete growth medium. After 
incubation for 24 h the test agents were added to the complete medium at the indicated 
concentrations and cells were incubated for a further 18 h. After treatment, 300-500 x 10
3
 cells were 
fixed in 70% iced-cold ethanol at -20°C for 20 min and then washed twice with phosphate buffered 
saline. Cells were incubated with 0.1 mg/mL RNAse and 36 g/mL PI at room temperature for 20 
min and the analysis was performed using a FACSCanto II flow cytometer (Becton–Dickinson, 
Mountain View, CA). 
 
2.7. Nucleic acids 
Salmon testes DNA was purchased from Sigma Chemical Company. The DNA concentration was 
determined using extinction coefficient 6600 M
-1
 cm
-1
 at 260 nm. pBR322 DNA was purchased 
from Fermentas Life Sciences. 
 
2.8. Quantitative platinum and phosphorus analysis 
The quantitative platinum and phosphorus analyses were performed according to a previous 
established method.
12
 Briefly, an aqueous solution of salmon testes DNA (9 x 10
-4
 M) was 
incubated at 37°C with test compound (stock solution 5 mM in DMSO) or cisplatin (stock solution 
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2 mM in 0.9% NaCl) to reach a [DNA]/[drug]=10. At fixed incubation time, aliquots of exact 
volume were collected and DNA was precipitated with Na-acetate (up to 0.3 M concentration) and 
cold ethanol (2 volumes). The precipitated DNA was washed with 70% ethanol, dried and then 
dissolved in a measured volume of milliQ water. The samples were then mineralised by treating 
with HNO3 (65%) at 90°C for 20 min. Finally the samples were re-suspended in diluted HCl to 
determine the P and Pt content. 
The analyses of P and Pt were performed by inductively coupled plasma atomic emission 
spectrometry (ICP-AES) at emission lines (P)=178.290 nm and (Pt)=214.423 nm. A 
Spectroflame Modula sequential and simultaneous ICP-spectrometer (ICP SPECTRO Arcos with 
EndOnPlasma torch) equipped with a capillary cross-flow Meinhard nebulizer was used (Spectro 
Analytical). Analytical determinations were performed using a plasma power of 1.2 kW, a 
radiofrequency generator of 27.12 MHz and an argon gas flow with nebulizer, auxiliary, and 
coolant set at 1, 0.5 and 14 L min
1
, respectively. 
 
2.9. DNA topoisomerase relaxation assay 
Supercoiled pBR322 plasmid DNA (0.25 µg) was incubated for 30 min at 37°C in 20 L reaction 
buffer containing test compound dissolved in DMSO (0.5 L) at indicated concentrations, then 1U 
topoisomerase II (USB Corporation) or 2U topoisomerase I (Topogen) were added and reactions 
performed for further 60 min at 37°C. 
Reactions were stopped by adding 4 µL stop buffer (5% SDS, 0.125% bromophenol blue and 25% 
glycerol), 50 µg/mL proteinase K (Sigma) and incubating for a further 30 min at 37°C. The samples 
were separated by electrophoresis on 1% agarose gel at room temperature. The gels were stained 
with ethidium bromide 1 µg/mL in TAE buffer, transilluminated by UV light, and fluorescence 
emission was visualized by a CCD camera coupled to a Bio-Rad Gel Doc XR apparatus. 
2.10 Topoisomerase II-mediated DNA cleavage 
Reaction mixtures (20 μL) containing 10 mM Tris-HCl (pH= 7.9), 50 mM NaCl, 50 mM KCl, 5 
mM MgCl2, 0.1 mM EDTA, 15 μg/mL bovine serum albumine (BSA), 1 mM ATP, 0.25 μg 
pBR322 plasmid DNA, 10 U topoisomerase II (human recombinant topoisomerase II, USB), and 
test compounds dissolved in DMSO (0.5 L) were incubated for 60 min at 37°C. Reactions were 
stopped by adding 4 μL of stop buffer (5% SDS, 0.125% bromophenol blue and 25% glycerol) and 
50 μg/mL proteinase K (Sigma) and incubating for a further 30 min at 37°C. The samples were 
separated by electrophoresis on 1% agarose gel containing ethidium bromide 0.5 μg/mL at room 
temperature in TBE buffer (0.09 M Tris-borate and 0.002 M EDTA). 
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3. Results and discussion 
 
3.1 Chemistry 
The preparation of secondary amines ArCH2NH(CH2)3CH3 was carried out starting from the 
corresponding aromatic aldehydes ArCHO and according to a well known procedure
13
 reported in 
Scheme 1.  
 
n-BuNH
2
1
Ar =  Ph (1a, 73%)
        1-Npa (1b, 98%)
        9-Anthb (1c, 88%)
        2-Pyrc (1d, 98%)
EtOH, 
NaBH
4
 
Scheme 1. Synthesis of ArCH2NH(CH2)3CH3. a) Np = Naphtyl; b) Anth = Anthracenyl; c) Pyr = Pyrenyl. 
 
Briefly, aromatic aldehydes were reacted with n-butylamine in refluxing ethanol, affording the 
corresponding imines, which were not isolated, but easily identified by IR spectroscopy, where 
C=O stretching disappeared and C=N stretching was observed. The following, smooth reduction of 
the intermediates by sodium borohydride was carried out in situ and, after the usual work-up and 
purification procedures, amines ArCH2NH(CH2)3CH3 1a-d were obtained in very good yields 
(Scheme 1). Their spectroscopic characterization (IR, 
1
H and 
13
C NMR) is reported in the 
experimental part and is in agreement with the expected structures. 
As for the synthesis of platinum complexes, they were prepared by reacting the described secondary 
amines with cis-[PtCl2(PPh3)(NCMe)],
4a
 under experimental conditions allowing the precursor 
isomerization and the following substitution of coordinated nitrile,
4b 
to afford trans-
[PtCl2(PPh3){NH(Bu)(CH2Ar)}] (Scheme 2). The reactions, monitored by 
31
P NMR spectroscopy 
to detect the disappearing of the precursor signal, were completed in 2-3 hours and afforded, after 
the usual work-up procedures, crystalline samples of the desired complexes 2a-d in good yields. 
The same procedure was followed to prepare trans-[PtCl2(PPh3)(p-Tolu)] (3) in 95% isolated yield. 
New prepared complexes 2 and 3 were insoluble in water and ethanol, but soluble ([complex] > 5 
mM) in dimethylsulfoxide. 
 
 
Scheme 2. Synthesis of trans-[PtCl2(PPh3){NH(Bu)(CH2Ar)}]. a) Np = Naphtyl; b) Anth = Anthracenyl; c) Pyr = 
Pyrenyl. 
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The new platinum complexes were characterized by elemental analysis, IR and NMR (
1
H, 
13
C, 
31
P 
and 
195
Pt) spectroscopies. The most significant IR, as well as 
31
P and 
195
Pt NMR data are reported in 
Table 1. In the IR spectrum of each complex a narrow, medium-weak band was observed around 
3200 cm
-1
, attributable to coordinated amine N-H stretching, while both aromatic and saturated C-H 
stretching vibrations were observed between 3050 and 2900 cm
-1
. In 
31
P NMR spectra, a single 
signal with satellites was observed, thus confirming the chemio-
4b
 and stereoselectivity of the 
process; this datum was also confirmed by the presence, in the 
195
Pt NMR spectra, of a single signal 
with a doublet multiplicity. Moreover, both the observed chemical shifts and 
1
JP-Pt coupling 
constants were in agreement with data previously collected for analogous complexes
4b-d
 where the 
trans stereochemistry had been structurally determined.
4b
 For ease of comparison, data for trans-
[PtCl2(PPh3)(NHEt2)] are included in Table 1. 
 
Table 1. Some significant spectroscopic data for complexes 2. 
 
Compound ?̃? N-H (cm
-1
)
a
 
31
P NMR (ppm)
b
 
195
Pt NMR (ppm)
b,c 1
JP-Pt (Hz) 
2a 3195 5.25 -3669 3576 
2b 3205 4.09 -3620 3580 
2c 3250 4.16 -3618 3573 
2d 3229 4.05 -3618 3590 
trans-[PtCl2(PPh3)(NHEt2)]
d
 3219 4.30 -3612 3560 
a) FTIR (ATR); b) solvent = CDCl3; c) doublet; d) see ref. 4b. 
 
The coordination of amines to platinum was also evident in 
1
H NMR spectra, recorded in CDCl3 
solution. In each sample, NH originated a broad singlet signal around 4.1 - 4.4 ppm, where a further 
broadening near the baseline allowed to measure a 
2
JH-Pt coupling constant of ~ 80 Hz. Moreover, 
due to the presence of the chiral nitrogen (Table 2), the hydrogen nuclei on the amine moiety are 
diastereotopic and, hence, non equivalent. Thus, Hb and Hb´ (Table 2) originate two, well separated 
doublet signals, with a 
2
JH-H coupling constant of ~ 13 Hz, typically observed for coupling between 
geminal hydrogen nuclei.
14
 Two distinct signals of multiplet were observed, as expected, also for 
Hc and Hc´ (Table 2). The non equivalence of geminal hydrogen atoms was observed along the 
whole butyl chain, with Hd,d´ and He,e´ (Table 2) generating well separated sets of multiplets, 
despite their growing distance from the chiral centre. 
 
Table 2. Chemical shifts of diastereotopic hydrogens in 
1
H NMR spectra for trans-[PtCl2(PPh3){NH(Bu)CH2Ar}]. 
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Hb; Hb´ (, ppm) Hc; Hc´ (, ppm) Hd; Hd´ (, ppm) He; He´ (, ppm) 
2a (Ar = Ph) 4.50; 3.81 (0.69) 3.25; 2.66 (0.59) 2.24; 1.86 (0.38) 1.38; 1.38 (0) 
2b (Ar = 1-Np) 5.05; 4.17 (0.88) 3.29; 2.51 (0.78) 2.20; 1.77 (0.43) 1.31; 1.22 (0.09) 
2c (Ar = 9-Anth) 5.42; 5.27 (0.15) 3.46; 2.30 (1.16) 2.16; 1.73 (0.43) 1.21; 1.08 (0.13) 
2d (Ar = 2-Pyr) 5.28; 4.63 (0.65) 3.43; 2.60 (0.83) 2.22; 1.81 (0.41) 1.33; 1.23 (0.10) 
 
3.2 Antiproliferative activity 
The antiproliferative activity of the new complexes 2a-d and 3 was evaluated on a panel of human 
tumor cell lines: HeLa (human cervix adenocarcinoma), H460 (large cell lung carcinoma), MSTO-
211H (human biphasic mesothelioma), A2780 (human ovarian carcinoma) and A2780cis (human 
ovarian carcinoma cisplatin-resistant). The cisplatin was taken as reference drug. 
The results have been expressed as GI50 values, i.e. the concentration of compound able to induce 
the death of 50% of the cells with respect to a control culture, and have been reported in Table 3. 
 
Table 3. Cell growth inhibition values in the presence of examined complexes and cisplatin. 
 
 
a 
Values are the mean ± SD of at least three independent experiments; 
b
 taken as reference drug. 
 
The obtained results indicate for all complexes belonging to the 2 series the ability to exert a 
significant antiproliferative effect towards all cell lines taken into consideration. In particular, 2a-d 
show in all cases GI50 values lower than 20 M and interestingly, 2a, characterised by the less 
bulky Ar residue, appears the most active. Otherwise, complex 3, which differs from 2a for the 
Complex 
Cell Line 
GI50
a
 (μM) 
HeLa H460 MSTO-211H A2780 A2780cis 
2a 5.31±0.65 7.33±0.86 8.93±0.27 3.55±0.26 3.63±0.21 
2b 9.35±1.28 13.3±0.7 14.9±1.3 6.41±0.65 5.91±1.14 
2c 16.3±1.4 17.7±1.2 18.5±1.4 7.97±0.45 12.6±1.1 
2d 19.0±1.4 9.03±0.98 17.5±1.2 4.90±0.75 6.95±1.45 
3 >20 >20 >20 17.7±0.4 18.7±1.4 
cisplatin
b
 1.60±0.37 0.83±0.11 1.3±0.22 0.80±0.06 7.23±0.26 
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absence of the n-butyl residue and of the methylene spacer at the level of the secondary amine, 
shows a low cytotoxicity profile with GI50 values detectable only on A2780 and A2780cis cell lines. 
Taking into consideration the chemical structures of the novel 2a-c complexes, it is possible to 
observe an opposite relationship between cytotoxicity and the dimension of Ar residue in the 
secondary amines although the differences in GI50 values are quite small. Indeed, the benzyl-
substituted 2a exerts the highest cell effect, which decreases of about 1.7 and 2.6 times for the 
naphtyl (2b) and the anthracenyl derivative (2c), respectively. Otherwise, the pyrenyl derivative 2d 
shows an antiproliferative effect somewhat dependent on cell line. 
The well-known drug cisplatin, taken as reference compound, is more cytotoxic than the new trans-
platinum(II) complexes in all sensitive cell lines, showing GI50 values low micromolar or 
submicromolar. Moreover, as expected, in A2780cis cells a decrease in cytotoxicity of about one 
order of magnitude with respect to the sensitive A2780 cells, is attained. In this connection, it is 
interesting to note that unlike cisplatin, 2a-d induce a comparable effect on both sensitive and 
resistant A2780cis cells. In particular, 2a exerts on resistant cells an antiproliferative effect 
significantly higher with respect to that induced by the drug, thus suggesting the involvement of cell 
pathways different from those of cisplatin. 
 
3.3 Determination of apoptosis 
To investigate the mechanism of cytotoxicity induced by 2a on A2780cis cells, flow cytometry 
analysis was performed in the presence of Annexin V-FITC and DNA-specific dye propidium 
iodide. The results are shown in Fig. 1A as dot plots and the percentage data are reported as 
histograms in Fig. 1B. By increasing the concentration of 2a a notable decrease in viable cells is 
obtained, accompanied by a concurrent increase in apoptotic (both early and late apoptosis) cells. 
Actually, the percentage of viable cells is reduced from 88.2% in the absence of complex (control) 
to 43.2% after incubation for 18 h in the presence of 2a at 25 M. In the same experimental 
conditions, the percentage of apoptotic cells increases from 9.3% to 47.9%. Otherwise, the 
percentage of necrotic cells varies only scarcely, reaching a percentage of 8.9% at the maximum 
concentration of 2a taken into account. These results confirm the capacity of 2a to overcome the 
resistance of A2780cis, cisplatin-resistant ovarian cancer cells, and highlight its ability to induce the 
apoptotic pathway in a dose-dependent manner pointing to a different mechanism of action or to an 
additional molecular target with respect to cisplatin. On the basis of the above results, we 
investigated more in depth the biological effects of 2a and in particular, its ability to interact with 
some biomacromolecules. 
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Fig. 1. Flow cytometry analysis of cell death induced by 2a. (A) Dot plots of the flow cytometry analysis performed on 
A2780cis cells labelled with Annexin V-FITC and propidium iodide after 18 h of treatment with different 
concentrations of 2a. (B) The histograms show the percentage of viable (Q3), early and late apoptotic (Q4+Q2) and 
necrotic (Q1) cells. Values are the mean ± SD of four independent experiments. 
 
3.4 Binding to DNA 
It was already widely demonstrated that DNA constitutes the main target responsible for the 
antiproliferative activity of cisplatin.
15
 Moreover, for some trans-diiodophosphine Pt(II) complexes 
the interaction with DNA was demonstrated and a correlation of such ability with cytotoxicity was 
also supposed.
16
 In this connection, the capacity of the most active complex 2a to coordinate DNA 
was investigated by ICP-AES technique, in comparison with cisplatin (Fig. 2). In detail, salmon 
testes DNA platination was determined for both 2a and the drug, at incubation time from 0 to 48 
hours. Furthermore, in each sample also the total amount of phosphorus was estimated, as internal 
standard for DNA content.
12
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Fig. 2. Binding of cisplatin (A) and 2a (B) to salmon testes DNA (9x10
-4
 M) as a function of incubation time. 
[DNA]/[drug]=10.  
 
The performed quantitative evaluation indicates for complex 2a an ability to bind to DNA clearly 
lower with respect to that obtained for cisplatin. In particular, after 48 h of incubation in the 
presence of the reference drug, about 700 ppb of Pt is bound to DNA, while for 2a, an amount of 
about 200 ppb is detected in the same experimental conditions. These results appear in agreement 
with the data reported in Table 3, showing for the novel complex, GI50 values higher than those of 
the drug in all sensitive cells taken into consideration, i.e. a lower antiproliferative activity. Then, 
for both 2a and cisplatin a similar mechanism of action, involving the platination of DNA, could be 
assumed. Nevertheless, due to the ability of 2a to exert a comparable cytotoxic effect on both 
A2780 and A2780cis cells, the involvement of further intracellular targets was hypothesized and 
investigated. 
 
3.5 Effect on cell cycle distribution 
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Most anticancer drugs block the cell cycle in either the S or G2/M phase and also cisplatin inhibits 
cancer cell growth by arresting the cell cycle progression through these phases.
17-18
 
In order to compare the effect of 2a with that of cisplatin, flow cytometric analysis was performed 
on A2780 cells, stained with PI and analysed for DNA/cell content. The cells were incubated in the 
absence (control) or in the presence of different concentrations (from 1 to 15 M) of cisplatin or 2a, 
and the results are shown in Fig. 3A and B, respectively.  
In detail, for the reference drug a dose-dependent arrest in S phase is highlighted (Fig. 3A), as 
previously reported by some authors.
18 
Otherwise, complex 2a induces a notable increase in subG0 
population (Fig. 3B). Interestingly, the occurrence of a hypodiploid DNA peak can be retained 
indicative of apoptosis,
19
 and it appears in accordance with the ability of 2a to induce apoptosis on 
cells. 
 16 
 
Fig. 3. Cell cycle distribution of A2780 cells cultured in the presence of cisplatin (A) or complex 2a (B) for 18 h at 
indicated concentrations. 
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3.6 Effect on topoisomerases 
Topoisomerases are nuclear enzymes able to solve topological problems that arise during 
replication, transcription and chromosome segregation, as a consequence of the double-stranded 
helix nature of DNA.
20
 Moreover, due to their catalytic activity, which introduces into DNA single 
(topoisomerase I) or double (topoisomerase II) strand breaks, a role of these enzymes in the 
resolution of intermediates that are found in recombinational repair, was also postulated.
21
 
Furthermore, it is to underline that a significant decrease in the rate of repair of cisplatin-induced 
DNA interstrand cross-links was demonstrated in human glioblastoma cells after exposure to 
novobiocin, a known topoisomerase II inhibitor.
22
 Moreover, an increase in topoisomerase I and II 
activity was detected in cisplatin-resistant ovarian cancer and murine leukemia cell line, 
respectively
23,24
 and interestingly, a number of topoisomerase inhibitors showed notably 
cytotoxicity on cisplatin-resistant cells.
25-27
 Overall, these results suggest a role of topoisomerases in 
the occurrence of cisplatin resistance and, in this connection, the possible effect of 2a on catalytic 
activity of both topoisomerase I and II was evaluated (Fig. 4A and B, respectively). 
Figure 4A shows the effect of test complex on the relaxation of supercoiled plasmid DNA mediated 
by topoisomerase I. The supercoiled DNA (lane DNA) is relaxed by the enzyme into a series of 
topoisomers (lane topo I), characterised by lower electrophoretic mobility with respect to the 
supercoiled form. The complex 2a, tested at 5, 10 and 20 M concentration, appears unable to 
affect the catalytic activity of topoisomerase I also at the higher concentration taken into 
consideration, as demonstrated by the occurrence of the same pattern of topoisomers as in the 
control (lane topo I). Similar experiments were also performed, by incubating topoisomerase II 
(lane topo II) in the presence of the same concentrations of 2a (Fig. 4B). The obtained results show 
that 2a prevents the relaxation of DNA catalysed by the enzyme and notably, the inhibition is 
complete already at 10 M concentration, pointing out this complex as an effective inhibitor of 
topoisomerase II.  
 
 
 
Fig. 4. Effect of 2a on relaxation of supercoiled pBR322 DNA by human recombinant topoisomerase I (A) and II (B). 
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The structurally related 2b-d were also evaluated, in comparison with 2a, for the capacity to inhibit 
the relaxation activity of topoisomerase II and all test complexes showed a significant effect (Fig. 
5). 
 
 
 
Fig. 5. Effect of 2a-d on relaxation of supercoiled pBR322 DNA by human recombinant topoisomerase II. 
 
 
Some important clinically used antitumor anti-topoisomerase II agents, interfere with the enzyme 
activity by stabilizing a covalent intermediate, the cleavable complex, into a lethal damage for the 
cell.
28-30 
These drugs are called topoisomerase II poisons and their mechanism of action and role in 
the anticancer activity has been widely discussed.
31
 The occurrence of the cleavable complex can be 
highlighted experimentally by the enzyme-dependent formation of linear from supercoiled DNA. 
The ability of 2a to inhibit significantly the relaxation activity mediated by topoisomerase II 
prompted us to investigate if a poisoning effect could be demonstrated for this complex. Figure 6 
shows the results of the cleavable complex assay performed with topoisomerase II in the presence 
of 50 and 100 M concentrations of 2a. The m-AMSA, a well known topoisomerase II poison,32 
was taken as reference at 10 M concentration. The supercoiled pBR322 DNA (lane DNA) was 
relaxed by the enzyme (lane topo II) and the addition of m-AMSA induces, as expected, the 
formation of linear DNA. Also complex 2a appears able to stabilize the cleavable complex, even if 
the amount corresponding to the linear DNA appears lower and detectable at higher concentrations 
with respect to that induced by the reference drug. 
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Fig. 6. Effect of 2a on the stabilization of the covalent DNA-topoisomerase II complex. 
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4. Conclusions 
Platinum (II) complexes containing triphenylphosphine and N(butyl),N(arylmethyl)amino ligands 
were synthesised and studied. The evaluation of the cytotoxicity on a panel of human tumor cell 
lines showed the ability of the complexes to induce an interesting antiproliferative activity with GI50 
values in most cases in the low micromolar range. In particular, it is noteworthy the ability of the 
new complexes to exert a comparable cytotoxicity on both sensitive and resistant cell lines, with 
complex 2a as the most effective. The ability to overcome resistance prompted an investigation on 
the mechanism of action that revealed a different effect on cell cycle and, in particular, an 
interesting capacity to interfere with the catalytic activity of topoisomerase II. Based on the role 
played by this enzyme on the occurrence of resistance, it could be assumed that the inhibitory effect 
exerted by 2a-d could be responsible for overcoming the resistance. 
Considering the results obtained in this study, it may be concluded that the new trans platinum(II) 
complexes could represent a model for the development of novel trans-Pt(II) based drugs able to 
exert an antiproliferative effect on cisplatin resistant cells. 
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